Reportedly, AIFA, Italy’s medicines agency has approved the use of the single-dose COVID-19 vaccine produced by Johnson & Johnson following approval from the European drugs regulator last week. The J&J’s vaccine approval marks fourth to be allowed for use in the European Union after vaccines from Pfizer-BioNTech, AstraZeneca-Oxford University, and Moderna received approval for usage for those over 18 years of age.
“This is the fourth vaccine to be available with the important additional advantage of a single dose and ease of administration, therefore ideal for the setting of family doctors. From mid-April, an important reality,” stated AIFA’s general director Nicola Magrini on the agency’s website.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
